IL6 and congenital rubella syndrome: Although no data from randomized clinical trials suggest that early intervention reduces the risk of CAR T-associated cardiovascular morbidity, indirect evidence suggest that cardiovascular protection may be achieved when early treatment of CRS takes place with corticosteroids and anti-IL-6 mAbs (tocilizumab) [42].